The Painkiller Paradox: Why "Painkiller" Marketing Copy Creates Regulatory Risk for Australian Health Brands

Every health brand exists to relieve something. Faster recovery, less pain, better sleep, hormonal balance — these are not fringe promises, they are the category's entire commercial premise. The market rewards whoever communicates that relief most convincingly, which creates an obvious and rational incentive: sharpen the headline, lean into the outcome, say it like you mean it.

The problem is not that this instinct is wrong. The problem is that it is incomplete.

The TGA, AHPRA, and FSANZ each operate regulatory frameworks built precisely to assess outcome language in health advertising. In 2023–24, the TGA issued 147 infringement notices totalling $2.20 million — not against brands that were dishonest about what their products did, but against brands whose marketing said more than their regulatory approval permitted them to claim. The irony is structural: the copy that converts best is the copy most likely to exceed what the framework allows.

A product listed on the Australian Register of Therapeutic Goods (ARTG) as an AUST L medicine earns a specific set of approved indications — the exact wording a brand is permitted to use in advertising. This is not a suggested starting point. It is the legal ceiling.

Under the Therapeutic Goods Advertising Code 2021, s.4(1), advertising for listed medicines must not represent a product as being effective for a purpose other than those approved in its ARTG entry. In practice, this means the gap between "what the product is approved to claim" and "what would make someone buy it right now" is the precise territory where most listed medicine marketing creates compliance exposure.

The failure mode is incremental rather than deliberate. "Supports joint health" becomes "repairs joints." "Helps maintain energy levels" becomes "eliminates fatigue." Each comparative word added to the approved indication language moves the copy outside the ARTG entry without the marketing team necessarily realising the boundary has been crossed.

• Review the exact indication wording in your ARTG entry before drafting any outcome claim
• Any word stronger than the approved indication — "faster," "eliminates," "restores" — requires a separate approved indication that supports it
• The TGA does not distinguish between deliberate overclaiming and enthusiastic overclaiming — the copy is assessed on its face

Sports supplements and food-medicine interface products carry a compliance risk that is structurally different from, and in some ways more severe than, the AUST L indication problem. Many of these products are not listed on the ARTG at all — they are classified as food, which means FSANZ Standard 1.2.7 governs what health claims can be made, not the TGA Advertising Code.

The reclassification risk arises when a food-classified product makes therapeutic outcome claims — the language of a painkiller — that would only be permitted for a registered therapeutic good. Under the Therapeutic Goods Act 1989 and the TGA's Food-Medicine Interface Guidance Tool (FMIGT), a product making a therapeutic claim may be reclassified as an unapproved therapeutic good regardless of how it is formulated or labelled.

This is not a technicality. A pre-workout powder marketed with the claim "accelerates muscle recovery and reduces inflammation" may be correctly formulated as a food supplement, accurately described, and genuinely effective — and still be assessed as an unapproved therapeutic good on the basis of its advertising copy alone. The product did not change. The marketing made it something else in regulatory terms.

• Run all outcome language for food-classified products through the FMIGT before publishing
• Avoid efficacy language that implies a physiological mechanism — this is the clearest signal to the TGA that a food product is being marketed as a medicine
• FSANZ Standard 1.2.7 permits general level health claims with conditions — therapeutic outcome claims go beyond this and trigger TGA jurisdiction

Health practitioners are not marketing a product with an approved indication. They are marketing a service — which means the compliance risk lives not in product registration but in AHPRA's Advertising Guidelines (December 2020), which apply to all registered health practitioners advertising a regulated health service.

The painkiller dynamic here operates through two mechanisms.

The first is testimonials. Patient stories about clinical outcomes — "this fixed my back," "within three sessions the pain was gone" — are prohibited outright under AHPRA's Guidelines, s.133 of the Health Practitioner Regulation National Law. The prohibition applies regardless of whether the testimonial is accurate, consented to, or posted by the patient unprompted. A practitioner who reposts or endorses a patient's outcome testimonial takes on the compliance liability for it.

The second is implied guarantee language. Claims that create an "unreasonable expectation of beneficial treatment" breach the AHPRA Guidelines even without a specific testimonial. This includes language that promises outcome certainty — "eliminate your pain," "permanent relief," "guaranteed results" — rather than describing the nature of the service.

The particular risk for practitioners is retrospective. AHPRA advertising complaints can be assessed against content published years earlier. Content that looked fine at the time of posting, and that performed well commercially, may sit on a website or social profile accumulating liability long after the campaign it supported has ended.

• Remove all patient testimonials from digital channels — reposts of organic patient reviews carry the same liability as solicited testimonials
• Replace outcome-certainty language ("fix," "eliminate," "cure") with service-description language ("assess," "treat," "manage")
• Conduct a retrospective audit of all digital content — not just new publishing — given the retrospective nature of AHPRA complaint assessment

There is an honest tension in this article that needs naming directly.

Brands using painkiller copy sometimes do get ahead — at least in the short term. The campaign converts. The content performs. The creative team is praised for finally writing something that sounds confident. Meanwhile, brands trying to stay within permitted claim territory can feel like they are bringing a dictionary to a shootout.

This is a real dynamic, not a perception problem. It is also temporary.

Enforcement in Australian health advertising operates on a complaint-driven and active monitoring model. The TGA received 3,370 advertising reports in 2023–24. AHPRA assessed 775 complaints in 2024–25, a figure that has risen 104 per cent over two years. The gap between publishing painkiller copy and receiving an infringement notice is not a guarantee of safety — it is a countdown whose length is unknowable from the outside.

The competitive advantage of non-compliant copy is borrowed time. The compliance cost is paid later, at a moment not of the brand's choosing, at a price — up to $19,800 per TGA infringement notice, up to $120,000 per AHPRA offence for a body corporate — that has nothing to do with whether the product worked.

• Publishing without checking the complete advertisement’s overall impression.
• Treating one regulator’s checklist as coverage for every applicable framework.
• Failing to retain evidence showing what was reviewed and approved before publication.

CompliGUARD reviews the complete advertisement against TGA · AHPRA · FSANZ · ACCC requirements, identifies clause-level risks, proposes compliant wording, and retains the result in an audit trail before publication.

CompliGUARD provides compliance insights based on current regulatory guidance. Requirements and penalty units may change. This content does not constitute legal advice.